CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Transitioning Patients Back to the Community Setting After CAR T Therapy for B-Cell Lymphoma

October 17th 2025

Panelists discuss how the timing of community transition depends on ongoing toxicities and patient comfort levels, with continued communication essential for managing lingering effects like cytopenias and autonomic dysfunction.

Discussing the Risk of Secondary Cancers From CAR T Therapy in Patients With B-Cell Lymphoma

October 17th 2025

Panelists discuss how the extremely rare risk of T-cell malignancies after CAR T therapy should be contextualized against the certain mortality risk of untreated refractory lymphoma.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

CMV Reactivation Monitoring and the Management of Persistent Cytopenias

October 10th 2025

Panelists discuss how CMV monitoring should be implemented for patients who received extensive corticosteroids and how persistent cytopenias beyond 6 months warrant bone marrow evaluation.

Monitoring for the Late-Phase Toxicities of CAR T for B-Cell Lymphomas

October 10th 2025

Panelists discuss how community oncologists should manage long-term CAR T complications, including hypogammaglobulinemia, cytopenias, and opportunistic infections while maintaining communication with treating centers.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Case Study Showcases Potential Role of Targeted Therapy for Secondary T-Cell Lymphoma After CAR T-Cell Therapy

October 4th 2025

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Preventing the Early-Phase CAR T Toxicities for B-Cell Lymphomas

October 3rd 2025

Panelists discuss how preventive strategies like dexamethasone can reduce high-grade toxicities in high-risk patients while prophylactic tocilizumab is avoided due to increased neurotoxicity risk.

Predicting the Early-Phase CAR T Toxicities for B-Cell Lymphomas

October 3rd 2025

Panelists discuss how acute CAR T toxicities follow predictable patterns based on specific products, with cytokine release syndrome typically preceding neurotoxicity and inflammatory markers serving as early indicators.

Emerging Strategies Aim to Enhance Safety and Monitoring in CAR T-Cell Therapy

October 1st 2025

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

FDA Grants Fast Track Designation to UB-VV111 for R/R B-Cell Malignancies

September 30th 2025

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Removing Barriers and Expanding Access to CAR T Therapy for B-Cell Lymphoma

September 26th 2025

Panelists discuss how the dissolution of REMS requirements and availability of outpatient CAR T therapy have significantly improved access by reducing monitoring restrictions and caregiver requirements.

Communicating the Value of CAR T in the Treatment of B-Cell Lymphoma

September 26th 2025

Panelists discuss how community oncologists can overcome misconceptions about CAR T toxicity by understanding that the therapy has evolved to be safer, with shorter hospital stays and better outcomes.

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL

September 26th 2025

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

Sending Patients to Referral Centers for CAR T and Bispecific Antibody Treatment Decisions for B-Cell Lymphoma

September 19th 2025

Panelists discuss how community oncologists should navigate referral processes to academic centers and balance CAR T therapy against other emerging treatments like bispecific antibodies based on curative potential.

Improved Patient Outcomes With CAR T as an Early Line of Treatment

September 19th 2025

Panelists discuss how earlier referrals for CAR T therapy led to better outcomes due to healthier T cells, reduced need for bridging therapy, and improved survival benefits demonstrated in clinical trials.

CAR T Patient Eligibility for B-Cell Lymphoma

September 12th 2025

Panelists discuss how eligibility criteria for CAR T therapy have expanded over time, emphasizing that all patients meeting disease indications should be referred to treatment centers rather than having community oncologists make exclusion decisions.